Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Duloxetine
Drug ID BADD_D00734
Description Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686.[A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.[L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
Indications and Usage Authors unspecified: Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int. 2006 Oct;15(85):168-72.
Marketing Status Prescription
ATC Code N06AX21
DrugBank ID DB00476
KEGG ID D07880
MeSH ID D000068736
PubChem ID 60835
TTD Drug ID D01AXB
NDC Product Code 55700-605; 60760-461; 53002-1561; 50436-0198; 71610-403; 47335-383; 70518-3287; 71205-005; 0228-2890; 43547-381; 61919-422; 53002-1494; 71205-358; 46708-279; 70710-1539; 68788-7672; 43547-379; 63629-5174; 80425-0119; 47335-616; 70710-1537; 55154-4981; 68180-294; 65841-801; 55154-4980; 45865-816; 70518-1128; 46708-278; 46708-280; 63629-8748; 47335-382; 70710-1538; 49252-007; 68382-386; 71205-602; 70771-1345; 68084-692; 61919-483; 50090-4011; 50090-4709; 51655-237; 67877-263; 47335-618; 71205-445; 70771-1344; 68382-387; 71335-2017; 68788-7935; 27241-099; 50268-288; 68180-296; 65841-799; 71335-1672; 70518-1011; 31722-168; 0228-2892; 63629-5202; 67877-265; 68180-295; 27241-164; 65977-0035; 47335-381; 70518-1054; 60760-462; 50090-5940; 47335-619; 68382-385; 31722-169; 50268-287; 45865-813; 68084-683; 63629-8051; 70771-1346; 65841-800; 43547-380; 49252-008; 71205-525; 68071-4700; 50090-4708; 55700-628; 70518-2855; 68180-297; 47335-617; 70518-3177; 31722-581; 70518-1139; 31722-582; 27241-098; 49252-009; 27241-097; 55700-727; 71335-0402; 67877-264; 68788-7828; 31722-583; 71335-1964; 68084-675; 0228-2891; 50436-0199; 50268-286; 31722-170; 70518-2630
Synonyms Duloxetine Hydrochloride | Hydrochloride, Duloxetine | Duloxetine HCl | HCl, Duloxetine | LY 248686 | LY-248686 | LY248686 | Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987 | LY 227942 | LY-227942 | LY227942 | Duloxetine | N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide | N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine | Duloxetine, (+)-isomer | Cymbalta
Chemical Information
Molecular Formula C18H19NOS
CAS Registry Number 116539-59-4
SMILES CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Antidepressant drug level increased13.17.01.0260.000132%Not Available
Opiates positive13.17.02.0130.000035%Not Available
Charles Bonnet syndrome06.02.06.016; 19.10.02.0130.000132%Not Available
Tachyphrenia19.10.03.010; 17.03.03.0070.001058%Not Available
Hyponatraemic encephalopathy17.13.01.011; 14.05.04.0070.000595%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000331%Not Available
Sleep sex19.02.03.011; 17.15.02.0080.000132%Not Available
Quality of life decreased13.18.01.0130.000331%Not Available
Gastrointestinal bacterial infection11.02.01.040; 07.19.02.0170.000132%Not Available
Stiff person syndrome17.05.02.018; 15.05.04.021; 10.04.10.0170.000463%Not Available
Neonatal behavioural syndrome17.02.05.058; 22.11.02.007; 18.04.04.010; 15.05.04.0200.000198%Not Available
Meniscus injury15.07.03.006; 12.04.03.0080.000132%Not Available
Rapid eye movement sleep behaviour disorder19.02.03.010; 17.15.04.0080.000331%Not Available
Selective eating disorder14.03.02.024; 19.09.01.0120.000265%Not Available
The 26th Page    First    Pre   26    Total 26 Pages